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Following an acute hepatitis B virus (HBV) infection, clearance or persistence is determined in part by the
vigor and breadth of the host immune response. Since the human leukocyte antigen system (HLA) is an
integral component of the immune response, we hypothesized that the highly polymorphic HLA genes are key
determinants of viral clearance. HLA class I and II genes were molecularly typed in 194 Caucasian individuals
with viral persistence and 342 matched controls who had cleared the virus. A single class I allele, A*0301 (odds
ratio [OR], 0.47; 95% confidence interval [CI], 0.30 to 0.72; P  0.0005) was associated with viral clearance.
The class II allele DRB1*1302 was also associated with clearance (OR, 0.42; 95% CI, 0.19 to 0.93; P  0.03),
but its significance decreased in a multivariate model that included other alleles associated with disease
outcome as covariates. B*08 was associated with viral persistence both independently (OR, 1.59; 95% CI, 1.04
to 2.43; P  0.03) and as part of the conserved Caucasian haplotype A*01-B*08-DRB1*03. The B*44-Cw*1601
(OR, 2.23; 95% CI, 1.13 to 4.42; P  0.02) and B*44-Cw*0501 (OR, 1.99; 95% CI, 1.22 to 3.24; P  0.006)
haplotypes were also associated with viral persistence. Interestingly, both the B*08 haplotype and DR7, which
forms a haplotype with B*44-Cw*1601, have been associated with nonresponse to the HBV vaccine. The
associations with class I alleles are consistent with a previously implicated role for CD8-mediated cytolytic-
T-cell response in determining the outcome of an acute HBV infection.
Worldwide, chronic hepatitis B affects an estimated 350 mil-
lion persons and is the leading cause of cirrhosis and hepato-
cellular carcinoma (20). Infection with hepatitis B virus (HBV)
in adulthood results in viral persistence and development of
chronic hepatitis in 5 to 10% of cases, but factors that deter-
mine viral persistence or clearance are not well understood.
Certain groups of individuals are known to be at increased risk
of developing chronic hepatitis B, including those who are
human immunodeficiency virus (HIV) seropositive, male, im-
munosuppressed, and elderly at the time of infection (17). In
addition, the host immune response plays a key role in deter-
mining the outcome, since a vigorous, polyclonal cytotoxic-T-
lymphocyte (CTL) response correlates with viral clearance (9,
25). These immune responses may be genetically determined,
since twin and family studies have suggested an inherited com-
ponent in the development of chronic hepatitis B (3, 21).
The immune response is coordinated by the human leuko-
cyte antigen (HLA) class I and class II molecules, which
present foreign antigens to CD8 cytolytic T cells and CD4
helper T cells, respectively. The genes encoding these mole-
cules are the most polymorphic in the human genome and are
ideal candidates for the investigation of association with HBV
outcomes.
HLA class II genes have previously been examined with
respect to HBV outcomes. The largest study, which was from
The Gambia, demonstrated an association between DRB1*
1302 and viral clearance (31). This finding was replicated in a
small study of Caucasian subjects from Germany (16). We and
others have noted a diverse array of additional class II associ-
ations (1, 28, 32, 33, 35), whose inconsistencies may be due to
small, heterogeneous study populations and variability in typ-
ing methods (29). Surprisingly, HLA class I alleles have never
been comprehensively examined despite their critical role in
mediating CTL responses. Thus, using a large cohort of Cau-
casian individuals with well-defined viral clearance or persis-
tence, we molecularly typed HLA class I and class II genes to
determine associations of their polymorphisms with the out-
come of HBV infection.
MATERIALS AND METHODS
Study subjects. Subjects in this study were participants in one of four studies:
(i) AIDS Link to Intravenous Experience, which is an ongoing study of 2,921
injection drug users enrolled in Baltimore from February 1988 to March 1989
(34), (ii) the Multicenter Hemophilia Cohort Study (MHCS), which is a pro-
spectively monitored cohort of 2,056 persons with hemophilia, von Willebrand’s
disease, or a related coagulation disorder from 16 comprehensive hemophilia
treatment centers enrolled between 1982 and 1996 (14), (iii) the Hemophilia
Growth and Development Study (HGDS) which is a continuing study of 333
children and adolescents with hemophilia enrolled between March 1989 and May
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1990 (15), and (iv) the Multicenter AIDS Cohort Study (MACS), which is an
ongoing study of 5,622 homosexual men enrolled in one of four cities in the
United States between 1984 and 1985 and between 1987 and 1991, as previously
described (10, 18). A nested case-control design was used such that case patients
were subjects persistently infected with HBV and controls were subjects who
were able to clear the virus. Each case was matched to two controls from the
same cohort based on factors that have been associated with HBV outcomes,
including age within 10 years, gender, and HIV status. Subjects were eligible to
be tested for viral persistence (cases) if they had (i) a baseline positive hepatitis
B surface antigen (HBsAg) test, (ii) a second specimen available for testing, and
(iii) peripheral blood mononuclear cells available to be transformed into cell
lines. Subjects were considered persistently infected with HBV if they tested
positive for HBsAg at two visits separated by a minimum of 6 months. Testing for
antibodies against hepatitis B core antigen (anti-HBc) and HBsAg (anti-HBs)
was performed as needed to exclude primary HBV infection. Individuals with
viral clearance (controls) were positive for anti-HBc and anti-HBs without the
presence of HBsAg at two time points separated by a minimum of 6 months.
HBV status of the HIV-positive subjects was defined before highly active anti-
retroviral therapy was available. We restricted our study to Caucasian subjects,
since numbers representing other ethnic groups were too small to discriminate a
significant effect by race (51 black subjects with viral persistence). Informed
consent was obtained from all participants, and the study was approved by the
institutional review boards at all participating institutions.
Serologic testing. All serum specimens were stored at 70°C until testing for
HBV and HIV serology using commercially available kits and manufacturer’s
specifications.
HLA typing. An Epstein-Barr virus-transformed cell line was established for
each subject, and DNA was isolated from these cell lines by phenol-chloroform
extraction. High-resolution (allele level) HLA class I genotyping was carried out
by using the standard sequence-specific oligonucleotide (SSO) probe typing
protocols developed by the 13th International Histocompatibility Workshop
(http://www.ihwg.org/protocols/protocol.htm). HLA-A, -B, and -C genes were
amplified by using locus-specific PCR primers flanking exons 2 and 3, the poly-
morphic segments of the class I genes. The 1-kb PCR products were blotted onto
nylon membranes and hybridized with a panel of SSO probes. HLA alleles were
assigned by the reaction patterns of the SSO probes based on known HLA
sequences. For samples with ambiguous SSO typing results, exons 2 and 3 were
sequenced.
Class II molecular typing was done by single-strand conformational polymor-
phism (7) in combination with PCR-SSO. For PCR-SSO, the protocol was also
based on the 13th International Histocompatibility Workshop and primers were
designed to amplify exon 2.
Statistical analysis. All analyses were performed with SAS version 6.12 (SAS
Institute, Cary, N.C.). In order to reduce the number of comparisons with
inadequate power, low-frequency alleles (3%) were not analyzed. Odds ratios
(ORs), which reflect the likelihood of a subject’s carrying a specific allele if that
subject is persistently HBV infected, and P values were calculated by using
conditional logistic regression. Known haplotypes composed of alleles that were
significantly associated with disease outcome (i.e., P  0.05) were also examined
by using conditional logistic regression. We further examined all alleles associ-
ated with either persistence or clearance (P  0.05) using a forward stepwise
multivariate analysis. The allele with the lowest P value was placed in the model
first, and subsequently each allele with a P value of 0.05 was manually added
to the model. An allele was retained in the model if its P value remained 0.05.
Potential effects of heterozygosity on HBV outcomes were tested separately
for the class I and II loci, using conditional logistic regression with the ORs
reflecting the likelihood of persistence if heterozygous. Initially, heterozygosity
was defined as having nonidentical alleles at all class I loci tested or at all class
II loci tested. Subsequently, heterozygosity was examined at each class II locus
individually in a univariate analysis. All of the class II loci were included as
separate variables in a multivariate model to assess which locus had a stronger
association.
RESULTS
A total of 194 individuals fulfilled our criteria for a persistent
HBV infection and were matched to 342 individuals with viral
clearance. Of the persistently HBV-infected individuals, 151
(77.8%) came from the MACS cohort, and the remaining 43
came from one of the other three cohorts. Of 46 individuals
with viral persistence (30 from the MACS, 12 from the HGDS,
1 from the MHCS, and 3 from AIDS Link to Intravenous
Experience), only one control subject met the selection crite-
ria. Although matching criteria allowed a 10-year age differ-
ence, 95% of the controls matched cases within a 5-year range,
and the mean ages of the cases and controls were similar, 30.7
and 30.5 years, respectively. In addition, the groups were sim-
ilar with respect to the other matching criteria, with 99% being
male and 69% being HIV seropositive.
Associations with viral clearance. HBV clearance was asso-
ciated with only one class I allele, HLA-A*0301, with an OR of
0.47 and a 95% confidence interval (95% CI) of 0.30 to 0.72 (P
 0.0005) (Table 1). The A*0301 association appeared to be
codominant, since the presence of two A*0301 alleles was
more protective than a single copy (Mantel-Haenszel test for
trend, P  0.0007). This allele appeared protective in each
cohort, but protection was significant only in members of the
MACS, the largest cohort in the study. Of the 13 individuals
homozygous for A*0301, 11 experienced viral clearance. The
known A*0301-B*07 haplotype was not significantly associated
with viral clearance (P  0.16). In a multivariate model, which
included the alleles associated with persistence (see below),
the OR for A*0301 was unchanged (P  0.0008) (Table 2).
An analysis of the class II loci showed an association of the
allele DRB1*1302 with viral clearance (OR, 0.42; 95% CI, 0.19
to 0.93; P  0.03). However, when DRB1*1302 was added to
TABLE 1. HLA alleles associated with HBV clearance and











A*0301 15.7 8.1 0.47 0.30–0.72 0.0005
DRB1*1302 4.9 2.1 0.42 0.19–0.93 0.03
Alleles associated with
persistence
B*08 8.1 12.2 1.59 1.04–2.43 0.03
B*44 11.9 19.4 1.82 1.27–2.60 0.001
Cw*0501 6.8 12.1 1.81 1.16–2.82 0.009
Cw*1601 2.4 5.3 2.14 1.09–4.18 0.03
DQB1*0201 20.1 27.8 1.56 1.15–2.09 0.004












B*44–Cw*1601 2.4 5.4 2.23 1.13–4.42 0.02
B*44–Cw*0501 5.3 10.4 1.99 1.22–3.24 0.006
B*44–DRB1*0701 4.6 7.8 1.83 1.06–3.15 0.03
B*44–Cw*1601- 2.0 4.3 2.21 1.04–4.71 0.04
DRB1*0701
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the multivariate model the OR was stable (0.46), but it was
borderline significant (P  0.06) (Table 2).
Associations with viral persistence. Four class I alleles were
associated with viral persistence: B*08 (OR, 1.59; 95% CI, 1.04
to 2.43; P  0.03), B*44 (includes HLA-B*4402 and HLA-
B*4403) (OR, 1.82; 95% CI, 1.27 to 2.60; P  0.001), Cw*0501
(1.81; 95% CI, 1.16 to 2.82; P  0.009), and Cw*1601 (OR,
2.14; 95% CI, 1.09 to 4.18; P 0.03) (Table 1). In addition, two
class II alleles, DQB1*0201 (OR, 1.56; 95% CI, 1.15 to 2.09; P
 0.004) and DRB1*0301 (OR, 1.66; 95% CI, 1.13 to 2.42; P
0.009), were associated with viral persistence. In the multivar-
iate model, which included alleles associated with viral clear-
ance, only B*08 (P 0.02) and B*44 (P 0.002) were retained
(Table 2).
The two class II alleles significant in the univariate analysis
along with B*08 are often inherited as the conserved haplotype
A*01-B*08-DRB1*0301-DQA1*0501-DQB1*0201. The associ-
ation of this haplotype with viral persistence was similar in
magnitude to the individual associations of B*08, DQB1*0201,
and DRB1*0301 (OR, 1.58; 95% CI, 0.93 to 2.68; P  0.09). In
order to determine whether B*08 or either of these class II
alleles had the stronger association, we excluded people with
the haplotype and tested the associations of B*08, DQB1*0201,
and DRB1*0301 individually. B*08 alone was the most predic-
tive (OR, 2.03) of persistence compared to DQB1*0201 (OR,
1.42) and DRB1*0301 (OR, 1.40), concurring with the results
of the multivariate analysis.
B*44 forms a haplotype with two of the other alleles asso-
ciated with viral persistence, Cw*0501 and Cw*1601. The as-
sociation of B*44-Cw*0501 (OR, 1.99; P  0.006) and B*44-
Cw*1601 (OR, 2.23; P  0.02) with viral persistence was
similar in magnitude to that of the individual alleles. The
extended haplotype B*44-Cw*1601-DRB1*0701 was also asso-
ciated with viral persistence (OR, 2.21; P  0.04). Cw*1601
was observed only in the presence of B*44, so it was not
possible to examine its effects independent of B*44. However,
the strength of the B*44 association among individuals without
either C allele was weaker (OR, 1.10). The same was also true
of the association of Cw*0501 among individuals without B*44
(OR, 1.72).
HLA heterozygosity and HBV outcomes. We tested the hy-
pothesis that being fully heterozygous at the HLA class I or II
loci is advantageous for viral clearance since, on average, het-
erozygotes are expected to present a wider array of antigenic
epitopes to the T cells (13). There was no protection due to
complete class I heterozygosity defined either by the two-digit
(serological equivalent) (OR, 0.76; 95% CI, 0.50 to 1.14; P 
0.18) or the four-digit (high-resolution) nomenclature (OR,
0.69; 95% CI, 0.45 to 1.07; P  0.10) (Table 3). On the other
hand, viral clearance was more common among individuals
who were heterozygous at all class II loci (OR, 0.62; 95% CI,
0.40 to 0.95; P  0.03). Next, potential confounding effects of
HLA-DQB1*0201 and HLA-DRB1*0301, class II alleles asso-
ciated with viral persistence, were excluded by removing indi-
viduals with these alleles from the zygosity analysis. The pro-
tective effect of heterozygosity on viral clearance was
independently significant (OR, 0.41; 95% CI, 0.19 to 0.85; P 
0.02). Heterozygosity at DQB1 was most strongly associated
with viral clearance in a univariate analysis of individual class
II loci (OR, 0.50; 95% CI, 0.31 to 0.83; P  0.008) and in a
multivariate model of all class II loci (Table 3).
DISCUSSION
In this comprehensive study of HLA class I and class II
genetic effects on the outcome of HBV infection in Caucasians,
A*0301 and DRB1*1302 were associated with a 2-fold increase
in HBV clearance, whereas B*08 and two B*44 haplotypes
were associated with a 1.5-fold increase in viral persistence.
It is notable that overall, the class I alleles have the strongest
associations, suggesting that the CD8 CTLs are important in
determining viral clearance or persistence. These findings con-
cur with the recent demonstration that chimpanzees acutely
infected with HBV and then depleted of CD8 T cells were
unable to eliminate the virus (27).
B*08 and its extended haplotype (A1-B8-DR3-DQ2) have
been associated with other immune-mediated diseases, includ-
ing autoimmune hepatitis (22, 24). In 57 to 88% of those
instances, B*08 is observed on this haplotype (24). Here, B*08
appeared to be more predictive of outcome than the other
alleles in the haplotype. Functional studies of individuals with
the A*01-B*08-DR3 haplotype have suggested a defect in early
T-cell activation (5) and decreased production of type 1 cyto-
kines, including interleukin 2, gamma interferon, and interleu-
kin 12 (4). Decreased natural killer cell activity has also been
TABLE 2. Final multivariate model combining alleles associated
with clearance and persistence with a P value of 0.05 from
univariate analysisa
Allele OR 95% CI P
B*08 1.66 1.08–2.55 0.02
B*44 1.81 1.25–2.60 0.002
A*0301 0.47 0.30–0.73 0.0008
DRB1*1302 0.46 0.21–1.04 0.06
a DRB1*1302 was borderline significant but has previously been associated
with HBV clearance; thus, it is presented here in the final model. Alleles con-
sidered in the multivariate model include all alleles significant in univariate
analysis, specifically, A*0301, DRB1*1302, B*08, B*44, Cw*0501, Cw*1601,
DQB1*0201, DRB1*0301.
TABLE 3. Association of HLA class I and class II heterozygosity
and hepatitis B virus outcomes
Frequency (%) of all
heterozygous






2-digit nomenclature 74.9 70.0 0.76 0.50–1.14 0.18
4-digit nomenclature 79.5 73.8 0.69 0.45–1.07 0.10
Class II 77.8 69.7 0.62 0.40–0.95 0.03
Univariate
DQA1 81.6 76.2 0.70 0.44–1.01 0.12
DQB1 86.9 78.8 0.50 0.31–0.83 0.008
DRB1 91.4 86.9 0.56 0.32–1.00 0.05
Multivariate
DQA1 NA NA 1.12 0.58–2.14 0.74
DQB1 NA NA 0.50 0.26–2.14 0.05
DRB1 NA NA 0.80 0.34–1.89 0.61
a NA, not applicable.
VOL. 77, 2003 HLA AND CHRONIC HEPATITIS B 12085
 o
n








noted in people with this haplotype (8). However, neither the
mechanism nor the precise gene responsible for these findings
has been elucidated, thus retaining the possibility that B*08
may be at least partly responsible for these phenotypes.
Although B*44 on haplotypes with both Cw*1601 and
Cw*0501 was associated with viral persistence, B*44 in the
absence of Cw*1601 and Cw*0501 was not. The stronger as-
sociation with the haplotypes may indicate that these alleles
are simply markers of the true disease allele through linkage
disequilibrium. The B*44-Cw*1601 haplotype often includes
the class II allele DRB1*0701, whose serological equivalent
(DR7) has been associated with viral persistence in a small
study from Qatar (1). However, in our study, DRB1*0701 alone
was not significantly associated with HBV persistence (OR,
1.23; 95% CI, 0.87 to 1.75; P  0.25).
Poor response to the HBsAg recombinant form of HBV
vaccine has been associated with some of the same alleles
associated with viral persistence in the present study, suggest-
ing similarities in the immune defect leading to viral persis-
tence and vaccine nonresponsiveness. Several studies have
demonstrated nonresponse to HBV vaccine among individuals
with the extended A*01-B*08 haplotype (2, 11, 19). DR7 has
also been reported to be associated with nonresponse to hep-
atitis B vaccine (11, 12, 23). In the one study that examined
HLA-A and -B genes, B*44 was more common in nonre-
sponders (40.7%) than in responders (23.9%) (23).
A*0301 was significantly associated with viral clearance in a
multivariate model. Examination of the A3 supertype, which
includes A*0301 and other A alleles with cross-reactive
epitopes (26), indicated that it could not account for the
A*0301 association. The molecule encoded by A*0301 may be
particularly efficient at presenting HBV epitopes to the CD8
T cells, but functional studies are necessary to confirm this
hypothesis.
DRB1*1302, an allele that has been associated with HBV
clearance in The Gambia (31), was the only other allele asso-
ciated with viral clearance here. The borderline significance of
this allelic effect in the multivariate analysis may have been a
consequence of its low frequency (3.8%). Alternatively, the
prominence of this allele in the Gambian study may indicate
greater importance in certain ethnic groups or in those who
acquire infections in infancy or early childhood.
The association of class II heterozygote advantage con-
firmed findings for the Gambian cohort (30). The multivariate
analysis suggested that the effect of class II heterozygosity is
due primarily to the DQB1 locus. Class I zygosity may also be
predictive of outcome to HBV infection, and our failure to
detect such an association may reflect insufficient statistical
power.
There are three primary limitations to this study. First, Bon-
ferroni correction for multiple comparisons would have ex-
cluded all but the association of A*0301 with viral clearance.
However, that statistical maneuver for genetic association
studies is controversial; its conservative overcorrection likely
leads to type II error (6). Our multivariate analysis, not per-
formed in previous HLA studies, highlighted the alleles that
are independently associated with either viral clearance or
persistence and strengthens our univariate findings. Further-
more, the biologic plausibility of those associations linked to
vaccine nonresponsiveness makes them worthy of further in-
vestigation. Second, despite the large sample size, we had lim-
ited power to detect associations with very-low-frequency al-
leles. Third, we combined several cohorts in this study and
acknowledge that we did not have the power to test each allele
individually in each cohort. Thus, the associations we detected
may not apply to every population and we may also have
missed associations that are operative only in certain popula-
tions. Further research, such as by replication in another co-
hort, is needed to confirm our findings.
The data reported herein support a role for HLA molecules,
particularly class I, in determining the outcome of a HBV
infection and may provide clues regarding the pathogenesis of
HBV infection. Functional studies are needed to understand
the basis for these associations and the link between the genes
associated both with viral persistence and with nonresponse to
the HBV vaccine.
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